H.C. Wainwright Upgrades Cardiff Oncology After Nerviano Settlement Clears Onvansertib Path
The catalyst: an out-of-court deal that keeps exclusive rights to onvansertib. Cash remains tight.
/ 3 items
#CRDF↓
Cardiff Oncology Downgraded by Two Analysts After Nerviano Terminates Onvansertib License
Cardiff was downgraded by TD Cowen and H.C. Wainwright after Nerviano Medical Sciences terminated the onvansertib license agreement. Company calls termination invalid and is fighting in court.
Cardiff Oncology Drops 34% After CEO and CFO Resign
Cardiff Oncology shares fall sharply as CEO and CFO step down amid leadership transition; interim CEO appointed to guide next phase of drug development.